Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has provided an update.
Amplia Therapeutics has initiated a new clinical trial in Australia to test the combination of its FAK inhibitor, narmafotinib, with the chemotherapy regimen FOLFIRINOX in patients with newly diagnosed metastatic pancreatic cancer. This trial, which is also set to commence in the USA, aims to explore the safety, tolerability, and efficacy of this combination, potentially offering improved outcomes for patients. The trial’s initiation underscores Amplia’s strategic focus on fibrotic cancers and its commitment to advancing innovative therapies in oncology.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis treatment. The company focuses on fibrotic cancers such as pancreatic and ovarian cancer and is also exploring treatments for chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 7,180,197
Technical Sentiment Signal: Buy
Current Market Cap: A$92.43M
For a thorough assessment of ATX stock, go to TipRanks’ Stock Analysis page.